President / CEO / Board Member
John is Co-Founder, President and CEO of Aceragen, leading the effort to acquire ACG-801 and the funding to support its development. He has extensive experience in the orphan and rare disease field, having spent a significant portion of his career developing therapeutic products in this area.
Prior to Aceragen, John co-founded and was President and CEO of Spyryx Biosciences, a company he spun out of UNC-Chapel Hill to develop inhaled peptides for cystic fibrosis. Under his leadership Spyryx raised over $23 million in venture capital with a top syndicate of investors, executed a $5 million collaboration with the Cystic Fibrosis Foundation, and advanced the lead program into an international Phase 2 study.
Previously, John held the position of Vice President, Corporate Development with Synageva BioPharma, a biotechnology company developing enzyme replacement therapies for untreated lysosomal storage disorders. John played key roles in establishing Synageva’s product portfolio and in taking the company public via a reverse merger with Trimeris. Earlier, John was the Vice President, Business Development for Javelin Pharmaceuticals and a senior business development leader with Eurand Pharmaceuticals, both specialty pharma companies.
John received his Bachelors degree in Biological Sciences from Clemson University and his Masters degree in Technology Management from the Wharton School of Business at the University of Pennsylvania.